On Thursday, August 6, 2026, Hypera (HYPE3) reported net income from continuing operations of R$ 490.0 million in the second quarter of 2026 (2Q26), an increase of 15.0% compared to 2Q25. Net revenue totaled R$ 2,336.7 million in the period, an advance of 8.5% in the same comparison, driven by a 7.6% increase in sell-out in the pharmaceutical retail segment.
Gross profit reached R$ 1,443.7 million in 2Q26, up 11.5% from the previous year, with a gross margin of 61.8%. EBITDA (earnings before interest, taxes, depreciation and amortization) from continuing operations was R$ 754.9 million, growth of 4.1%, with a margin of 32.3%. The company attributed the increase in net income, above EBIT, mainly to a 16.9% reduction in financial expenses, following a capital increase of R$ 1.5 billion at the end of 1Q26.
Operating cash flow reached R$ 819.2 million in 2Q26, an increase of 85.0% compared to 2Q25 and equivalent to 108.5% of EBITDA from continuing operations. Free cash flow totaled R$ 637.8 million in the quarter, supported by a lower level of purchases of property, plant and equipment and intangibles and by the reduction in inventories to R$ 1,927.0 million.
Hypera’s net debt ended June 2026 at R$ 5,903.5 million, a reduction of R$ 397.6 million compared to the end of 1Q26, equivalent to 2.1 times EBITDA from continuing operations for the last 12 months. Working capital investments came to represent 28% of the quarter’s annualized net revenue, compared to 32% in 2Q25.
The company approved the distribution of Interest on Equity (JCP) in the total amount of R$ 185.2 million, equivalent to R$ 0.26 per share. Hypera also highlighted its strategic partnership with Astellas for the commercialization of a non-hormonal treatment for menopause symptoms and the approval of Semavy by Anvisa, which marks its entry into the Brazilian GLP-1 analog market.
